Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with UAV Corp (OTC: UMAV), has successfully concluded the REVIVE Adaptive Platform Trial (NCT06128967), the largest Phase III study for Long COVID to date. This randomized, double-blind trial involved over 600 participants and was conducted in partnership with leading institutions including Stanford and Duke. The study's success, powered by Fifty 1 Labs' proprietary AI platform, highlights the efficacy of repurposed medicines in treating Long COVID, offering hope to millions affected by persistent symptoms post-COVID-19 recovery.
The trial's outcomes not only demonstrate the potential of drug repurposing and personalized medicine but also align with Fifty 1 Labs' ambition to lead the $320.6 billion functional medicine market. The company's innovative use of AI technology accelerates drug discovery and customization of treatments, setting a new standard in healthcare innovation. This milestone reflects Fifty 1 Labs' dedication to advancing global health through pioneering research and development, reinforcing its position in biotechnology and wellness.
